A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.

"Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days."

"The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days."